Live Feeds
● TRACKER Updated 11d ago · 78 sources tracked

Moderna Shares Double on Success of mRNA Cancer Vaccine

Moderna stock climbed about 8% over five sessions through November 5, closing at $241, as investors digested Phase 3 results showing its personalized mRNA vaccine intismeran combined with Merck's Keytruda cut melanoma recurrence or death risk by 42% and distant metastasis or death risk by 38%. A prespecified sensitivity analysis showed a 58% reduction after six months. The company also lifted its 2026 revenue growth forecast to 15%-25% from a previous ceiling of 10%, citing broader business improvement beyond the cancer program.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (78)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Moderna shares gained approximately 8% over five trading sessions through November 5, closing at $241.
  • ✓ Intismeran combined with Keytruda reduced the risk of melanoma recurrence or death by 42% in the Phase 3 INTerpath-001 trial.
  • ✓ The combination lowered the risk of distant metastasis or death by 38%.
  • ✓ A prespecified sensitivity analysis showed a 58% reduction in recurrence or death risk after six months.
🛡️ Source Corroboration: 78 independent reporting domains (92% confidence) ⏱ Read time: ~2 min

What changed

Moderna raised its 2026 revenue growth outlook to 15%-25% and shares rose 8% in five days to $241 as investors reassessed the personalized cancer vaccine's commercial trajectory.

Live updates

  1. Moderna shares surge on cancer vaccine data and raised revenue guidance

    Moderna stock climbed about 8% over five sessions through November 5, closing at $241, as investors digested Phase 3 results showing its personalized mRNA vaccine intismeran combined with Merck's Keytruda cut melanoma recurrence or death risk by 42% and distant metastasis or death risk by 38%. A prespecified sensitivity analysis showed a 58% reduction after six months. The company also lifted its 2026 revenue growth forecast to 15%-25% from a previous ceiling of 10%, citing broader business improvement beyond the cancer program.

    Why it matters

    The INTerpath-001 data, presented at ESMO 2026 and accepted by The New England Journal of Medicine, marked the first Phase 3 success for an mRNA cancer vaccine. The bespoke manufacturing process remains a scaling challenge, but the efficacy signal and upgraded guidance suggest the market is pricing in a durable oncology franchise alongside recovering COVID-19 and RSV sales.

    What is confirmed

    • Moderna shares gained approximately 8% over five trading sessions through November 5, closing at $241.
    • Intismeran combined with Keytruda reduced the risk of melanoma recurrence or death by 42% in the Phase 3 INTerpath-001 trial.
    • The combination lowered the risk of distant metastasis or death by 38%.
    • A prespecified sensitivity analysis showed a 58% reduction in recurrence or death risk after six months.
    • Moderna now expects 2026 revenue growth of 15% to 25%, up from previous guidance of up to 10%.

    What to watch next

    • FDA regulatory filing timeline for intismeran-Keytruda combination in high-risk melanoma
    • Commercial manufacturing scale-up plans for personalized mRNA vaccine production
    • Additional trial readouts in other tumor types such as non-small cell lung cancer
    Sources used for this update (4)
    1. fortune.com — Hachette’s CEO says AI shortcuts are creating a ‘worse C-suite'
    2. www.cnbc.com — Moderna (MRNA) earnings Q3 2026 - CNBC
    3. www.fool.com — Moderna Just Gave Investors Yet Another Thing to Cheer About
    4. finance.yahoo.com — Moderna Stock Rises 8% in Five Sessions as CEO Sees Cancer ...
    confidence 92%
  2. Moderna Shares Double Following Melanoma Vaccine Trial Success

    Moderna and Merck announced that their personalized mRNA cancer vaccine, combined with Keytruda, succeeded in a late-stage trial for high-risk melanoma. The Phase 3 data from the INTerpath-001 trial demonstrated that intismeran autogene paired with Keytruda reduced recurrence or death risk by 42% after surgery. Additionally, the therapy lowered distant metastasis or death risk by 38%. These findings were presented at ESMO 2026 and accepted by The New England Journal of Medicine. The clinical success caused Moderna shares to double, though the bespoke nature of the treatment creates potential scaling challenges.

    Why it matters

    Moderna is a Cambridge, Massachusetts-based biotechnology company that focuses on RNA therapeutics and mRNA vaccines. The company name combines modified, RNA, and modern. The successful late-stage melanoma trial results open a potential new pathway for treating the deadly skin cancer by using a copy of a messenger RNA molecule to carry protein instructions that stimulate an immune response.

    What is confirmed

    • Moderna and Merck reported Phase 3 INTerpath-001 data showing that intismeran autogene combined with Keytruda reduced the risk of recurrence or death by 42% in high-risk melanoma patients after surgery.
    • The treatment lowered the risk of distant metastasis or death by 38%.
    • The clinical trial results were presented at ESMO 2026 and accepted by The New England Journal of Medicine.
    • Moderna is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, focusing on RNA therapeutics and mRNA vaccines.
    • Moderna vaccines use a copy of a messenger RNA molecule to carry instructions for proteins to produce an immune response.

    What to watch next

    • Manufacturing scale and cost developments for bespoke mRNA cancer designs
    • Further updates on the commercial rollout and regulatory status of the melanoma vaccine
    Sources used for this update (6)
    1. www.modernatx.com — Pioneering mRNA technology - Moderna
    2. en.wikipedia.org — Moderna - Wikipedia
    3. finance.yahoo.com — Moderna, Inc. (MRNA) Stock Price, News, Quote & History - Yahoo...
    4. www.cnn.com — Moderna and Merck say melanoma vaccine succeeded in large trial
    5. investors.modernatx.com — Investor Relations - Moderna
    6. www.modernatx.com — Our Products
    confidence 100%
  3. Moderna Shares Rise as mRNA Cancer Vaccine Cuts Melanoma Risks

    Moderna and Merck reported Phase 3 INTerpath-001 data showing that intismeran autogene combined with Keytruda reduced the risk of recurrence or death by 42% in high-risk melanoma patients after surgery. The treatment also lowered the risk of distant metastasis or death by 38%. These results were presented at ESMO 2026 and accepted by The New England Journal of Medicine. While the clinical success drove stock growth, the therapy requires bespoke mRNA designs based on individual tumor DNA, creating potential challenges for manufacturing scale and cost.

    Why it matters

    mRNA technology is expanding beyond infectious diseases into oncology. This shift comes as traditional COVID-19 vaccine revenues decline for industry peers like Pfizer and BioNTech.

    What is confirmed

    • Intismeran autogene plus Keytruda cut the risk of recurrence or death by 42% in high-risk melanoma patients after surgery.
    • The combination therapy reduced the risk of distant metastasis or death by 38%.
    • The New England Journal of Medicine accepted the Phase 3 INTerpath-001 results.

    Still unconfirmed

    • The bespoke manufacturing model for the vaccine raises questions regarding cost, scale, and turnaround.
    • Moderna stock reached a new 52-week high on Wednesday.

    What to watch next

    • Friday's financial report regarding Moderna's pipeline affordability
    • Publication of the full study in The New England Journal of Medicine
    Sources used for this update (4)
    1. simplywall.st — Cancer Vaccine Win Could Be A Turning Point For Moderna Stock ...
    2. www.cfpublic.org — What the latest on mRNA vaccines means for cancer
    3. finance.yahoo.com — Maravai LifeSciences (MRVI) Q3 2026 Earnings Call Transcript
    4. finance.yahoo.com — Moderna Soared 8% on Cancer Data. Friday’s Report Shows Whether It Can Afford the Pipeline
    confidence 90%
  4. Moderna Shares Double on mRNA Cancer Vaccine Success

    Moderna's stock price has doubled following the success of its mRNA cancer vaccine in a Phase 3 trial. The vaccine, developed with Merck, showed a 42% reduction in melanoma death and recurrence risk when combined with Keytruda. This significant improvement in outcomes for melanoma patients has led to a surge in Moderna's stock price.

    Why it matters

    The mRNA cancer vaccine's success is a major breakthrough in the fight against cancer. Moderna's collaboration with Merck has yielded promising results, and the vaccine's potential to improve treatment options for melanoma patients is substantial. The stock market's reaction reflects the high hopes for this new treatment.

    What is confirmed

    • Moderna's mRNA cancer vaccine reduced melanoma recurrence or death risk by 42% in a Phase 3 trial.
    • The vaccine was developed in collaboration with Merck.
    • Moderna's stock price has doubled in value after the announcement.
    • The vaccine was tested in combination with Keytruda.

    Still unconfirmed

    • Moderna's stock price may continue to rise as investors price in the potential for the cancer vaccine to become a major treatment option.

    What to watch next

    • Regulatory approval for the mRNA cancer vaccine
    • Further data on the vaccine's efficacy and safety in longer follow-up periods
    • Market performance of Moderna's competitors in the cancer treatment space
    Sources used for this update (17)
    1. finance.yahoo.com — Yahoo Finance - Stock Market Live, Quotes, Business & Finance News
    2. www.marketbeat.com — MRNA News Today | Why did Moderna stock go up today? - MarketBeat
    3. www.merck.com — Merck | Home
    4. seekingalpha.com — Patient Capital Management Q3 2026 Commentary
    5. www.marketbeat.com — Top Biotech Stocks To Research - October 14th | MarketBeat
    6. en.sedaily.com — Moderna Cancer Vaccine Passes Phase 3 but Falls Short of Wall ...
    7. www.ynetnews.com — Great Britain
    8. biotech-today.com — Moderna’s 25% Plunge Exposes Cancer Vaccine Expectations
    9. coinpedia.org — Why Did Moderna Stock Crash 17% Despite Positive Cancer ...
    10. 247wallst.com — Moderna Jumps 4% Despite William Blair Downgrade on Valuation ...
    11. www.analyticsinsight.net — Moderna Shares Slide Despite Cancer Vaccine Cutting Melanoma ...
    12. www.biopharmadive.com — Lilly shuffles business structure; Novartis writes off part of Avidity deal | BioPharma Dive
    confidence 85%
  5. Moderna Shares Double on mRNA Cancer Vaccine Success

    Moderna's mRNA cancer vaccine, developed with Merck, has shown a 42% reduction in melanoma death and recurrence risk in a Phase 3 trial. The vaccine, combined with Keytruda, significantly improved outcomes for melanoma patients. This has led to a surge in Moderna's stock price, doubling in value after a 10% fall on October 16.

    Why it matters

    The vaccine's success is a significant advancement in cancer treatment, offering new hope for melanoma patients. The Phase 3 trial results demonstrate the potential of mRNA technology in cancer therapy. Moderna's stock performance reflects investor confidence in the company's innovative approach.

    What is confirmed

    • The mRNA cancer vaccine reduced melanoma death and recurrence risk by 42%.
    • The vaccine was tested in a Phase 3 trial in combination with Keytruda.
    • Moderna's stock price has doubled in value following the trial results.
    • The vaccine is a personalized mRNA cancer vaccine.
    • Six melanoma specialists consider the results a clinically meaningful advancement for melanoma patients.

    What to watch next

    • Future regulatory approvals for the mRNA cancer vaccine
    • Additional trial results for the vaccine in other cancer types
    • Moderna's stock performance in the coming weeks
    Sources used for this update (7)
    1. www.forbes.com — Download The Forbes App
    2. www.cnn.com — Experimental mRNA vaccine cuts risk melanoma returns by 42% - CNN
    3. time.com — A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42%
    4. www.cnbc.com — Moderna, Merck's cancer vaccine data a major advancement - CNBC
    5. wsvn.com — Experimental mRNA vaccine cuts risk that melanoma returns by 42% - WSVN 7News | Miami News, Weather, Sports | Fort Lauderdale
    6. www.emjreviews.com — mRNA Therapy Improves Melanoma Outcomes - ESMO 2026
    7. www.ajmc.com — Spring 2023 Conference Coverage | AJMC
    confidence 97%
  6. Moderna's mRNA Cancer Vaccine Cuts Melanoma Death, Recurrence by 42%

    Moderna's mRNA cancer vaccine, developed with Merck, has shown a 42% reduction in the risk of melanoma death and recurrence. The vaccine, combined with Keytruda, was tested in a Phase 3 trial and demonstrated a significant improvement in outcomes for melanoma patients. This development has led to a surge in Moderna's stock price, which has doubled in value. The company's stock had previously fallen 10% on October 16 following a massive rally driven by Phase 3 success for its personalized melanoma vaccine.

    Why it matters

    The success of Moderna's mRNA cancer vaccine is a significant development in the field of oncology, offering new hope for melanoma patients. The vaccine, which is customized for each patient to match their tumor, has shown promising results in reducing the risk of disease progression or death. This comes as Moderna's stock has experienced significant fluctuations in recent weeks, with a year-to-date surge of over 600 percent and a return to the Nasdaq-100.

    What is confirmed

    • Moderna's mRNA cancer vaccine, developed with Merck, reduces the risk of melanoma death and recurrence by 42%.
    • The vaccine was tested in a Phase 3 trial and demonstrated a significant improvement in outcomes for melanoma patients.
    • Moderna's stock price has doubled in value following the release of the trial results.

    What to watch next

    • Moderna's critical trial readout expected later this month
    • Analyst price targets and their impact on Moderna's stock price
    Sources used for this update (4)
    1. arstechnica.com — Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
    2. www.scientificamerican.com — Here’s what Moderna’s latest mRNA cancer vaccine data actually show
    3. www.thenationalherald.com — A Novel Mrna Cancer Vaccine Helps Reduce the Chances of Melanoma Patients’ Tumors Returning
    4. www.grandviewresearch.com — DNases, Ligases, And RNA Polymerases Market (2026 - 2033)
    confidence 95%
  7. Moderna Shares Dip 10% After Cancer Vaccine Rally

    Moderna stock fell 10% on October 16 following a massive rally driven by Phase 3 success for its personalized melanoma vaccine, intismeran autogene. Developed with Merck, the mRNA therapy combined with Keytruda reduced the risk of disease progression or death by 49 percent over five years. Despite a year-to-date stock surge of over 600 percent and a return to the Nasdaq-100, current analyst price targets remain below the share price. The company is now awaiting a critical trial readout expected later this month.

    Why it matters

    Intismeran autogene is the first personalized mRNA neoantigen therapy to pass a large Phase 3 trial. It uses custom-manufactured mRNA encoding roughly 34 patient-specific neoantigens to prevent cancer recurrence. This success marks Moderna's strategic shift from COVID-19 products toward oncology.

    What is confirmed

    • Intismeran autogene is the first mRNA cancer vaccine to meet a Phase 3 endpoint for recurrence-free and distant metastasis-free survival in Stage IIB-IV melanoma.
    • The vaccine was co-developed by Moderna and Merck and is administered alongside the immunotherapy drug Keytruda.
    • Five-year results showed a 49 percent reduction in disease progression or death compared to using Keytruda alone.
    • The Phase 3 study included more than 1,100 patients.
    • Moderna was added back to the Nasdaq-100 index following the positive oncology data.

    Still unconfirmed

    • Profit takers may possess information unknown to bulls regarding an upcoming trial readout.

    What to watch next

    • The results of the critical trial readout expected by the end of October 2026.
    • FDA approval status for intismeran autogene.
    • Outcomes of Phase 3 trials for non-small cell lung cancer (NSCLC) under the INTerpath-002, 009, and 014 studies.
    Sources used for this update (12)
    1. londondaily.com — Moderna and Merck's Personalized Cancer Vaccine Succeeds in ...
    2. www.biospace.com — Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earnings
    3. help.naver.com — Futures Flat As Oil Rebounds After Trump's "Energy Ceasefire" Unravels, Memory Stocks Slide | ZeroHedge
    4. www.fool.com — Forget the Recent Delivery Beat: Here's the Key Number That Will Decide Investors' Reaction to Tesla's Earnings | The Motley Fool
    5. www.foxbusiness.com — Great Business Leaders in America & Around the World | Fox Business
    6. contents.premium.naver.com — [잠옷입고 경제공부] 세계 무역지도를 바꿀 사건!
    7. 247wallst.com — Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
    8. finance.yahoo.com — Phase 3 Cancer Vaccine Success Could Change The Case For ...
    9. finance.yahoo.com — Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too ...
    10. www.smartcancer.org — Moderna Merck Cancer Vaccine Phase 3 Results 2026: Intismeran ...
    11. www.biopharmadive.com — Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study
    12. www.clintrialfinder.info — Intismeran Autogene (V940): First mRNA Cancer Vaccine to Meet ...
    confidence 95%
  8. Moderna Stock Surges Following Cancer Vaccine Milestone

    Moderna shares have more than doubled after the biotech company released successful trial data for intismeran autogene, its experimental melanoma vaccine co-developed with Merck. The treatment pairs the personalized mRNA vaccine with Merck's immunotherapy drug Keytruda. Five-year results demonstrate a 49 percent reduction in disease progression or death compared to Keytruda alone. This clinical milestone drove a nearly 600 percent surge in stock value this year and triggered Moderna's return to the Nasdaq-100 index.

    Why it matters

    The positive data marks a strategic shift for Moderna as the company diversifies its portfolio beyond its initial focus on COVID-19 vaccines. Former manufacturing leader Juan Andres has returned as Chief Operating Officer to oversee scaling for the personalized oncology vaccine. Meanwhile, broader market interest in RNA-based therapeutics continues to expand alongside national initiatives to accelerate cancer vaccine development.

    What is confirmed

    • Moderna and Merck are co-developing intismeran autogene, an experimental mRNA-based cancer vaccine designed to target individual patient tumor mutations.
    • Clinical data showed a 49 percent reduction in disease progression or death for melanoma patients receiving the combination of intismeran and Keytruda compared to Keytruda alone.
    • Moderna was added to the Nasdaq-100 index to replace Warner Bros. Discovery.
    • Juan Andres returned to Moderna as Chief Operating Officer to oversee manufacturing scale-up.

    Still unconfirmed

    • Moderna could play a significant role in a national effort to combat cancer through accelerated vaccine development initiatives.

    What to watch next

    • Regulatory review and approval decisions regarding intismeran autogene
    • Further expansion of Moderna's personalized mRNA vaccine platform into more complex conditions beyond melanoma
    Sources used for this update (12)
    1. stockstotrade.com — MRNA Jumps As Nasdaq-100 Inclusion And Cancer Pipeline Shift Momentum
    2. www.nature.com — Bioengineering strategies for improving the immunogenicity of mRNA vaccines | Signal Transduction and Tar....
    3. finance.yahoo.com — Why Moderna Stock Surged Today
    4. finance.yahoo.com — Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell?
    5. www.marketresearchfuture.com — RNA Based Therapeutics Market
    6. finance.yahoo.com — Moderna (MRNA) Is Up 18.4% After Cancer Vaccine Milestone And ...
    7. finance.yahoo.com — These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?
    8. finance.yahoo.com — Moderna’s (MRNA) Cancer Vaccine Breakthrough Drives Sharp ...
    9. finance.yahoo.com — Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick?
    10. finance.yahoo.com — Moderna Stock Skyrockets on Reports of U.S. Cancer Vaccine ...
    11. radio900.net — Moderna shares surge after it says its experimental mRNA ...
    12. contents.premium.naver.com — 📬 미국 주식 데일리 종목 분석 (2026.10.13)
    confidence 100%
  9. Moderna Expands Personalized mRNA Cancer Vaccine Platform

    Moderna shares have doubled following successful trial data for intismeran autogene, its experimental melanoma vaccine co-developed with Merck. Five-year results demonstrate a 49% reduction in disease progression or death, driving a nearly 600% surge in stock value this year. Amid strong investor enthusiasm and social media chatter, Nasdaq added Moderna to the Nasdaq-100 index to replace Warner Bros. Discovery before the market opened on October 9, 2026. Moderna also announced progress in expanding its personalized mRNA vaccine platform beyond melanoma to target more complex conditions.

    Why it matters

    The company advances its personalized mRNA cancer vaccine platform as investors await the complete data release in Madrid. Broader geopolitical dynamics also shape the industry, with transatlantic cooperation between the United States and Europe aiming to prevent China from establishing dominance in biotechnology capital, talent, and research.

    What is confirmed

    • Moderna shares have surged nearly 600% this year.
    • Intismeran autogene is co-developed with Merck and shows a 49% reduction in disease progression or death over five years.
    • Moderna joined the Nasdaq-100 index before the opening bell on October 9, 2026, replacing Warner Bros. Discovery.

    Still unconfirmed

    • US and Europe cooperation on biotechnology talent, capital, and research will prevent China from establishing dominance in the field.
    • Social media chatter highlights Moderna's remarkable stock climb this year.

    What to watch next

    • The complete data release in Madrid
    • Further expansion of the personalized mRNA platform beyond melanoma
    Sources used for this update (3)
    1. cepa.org — Forging a Transatlantic Biotechnology Partnership to Confront the China Challenge - CEPA
    2. www.quiverquant.com — Moderna Stock (MRNA) Opinions on Cancer Vaccine Trial Success
    3. www.gurufocus.com — Moderna (MRNA) Advances Personalized mRNA Cancer Vaccines ...
    confidence 100%
  10. Moderna Shares Climb on Melanoma Vaccine Data Ahead of Nasdaq Return

    Moderna shares have surged nearly 600% this year amid high expectations for its experimental melanoma vaccine, intismeran autogene, co-developed with Merck. Five-year results demonstrate a 49% reduction in disease progression or death. While investors rally around the personalized mRNA treatment, the broader market awaits the complete data release in Madrid. Meanwhile, Nasdaq announced that Moderna will join the Nasdaq-100 index before the opening bell on October 9, replacing Warner Bros. Discovery.

    Why it matters

    The surge in valuation follows positive Phase 3 results from the INTerpath-001 trial, which met primary endpoints for recurrence-free survival and distant metastasis-free survival when combined with Merck's Keytruda. Financial institutions have urged caution despite the clinical milestones, with Citi previously downgrading the stock due to extreme market expectations.

    What is confirmed

    • Moderna stock has surged nearly 600% this year on cancer vaccine trial results.
    • Five-year results with the Moderna and MSD melanoma jab show a 49% reduction in disease progression or death.
    • Nasdaq announced on October 1 that Moderna will join the Nasdaq-100 before the open on October 9, replacing Warner Bros. Discovery.

    Still unconfirmed

    • The complete trial data will be fully evaluated by the market following its presentation in Madrid.

    What to watch next

    • The full data readout scheduled to be presented in Madrid.
    • Moderna's official entry into the Nasdaq-100 index on October 9.
    Sources used for this update (5)
    1. pharmaphorum.com — Data builds behind Moderna's skin cancer vaccine
    2. 247wallst.com — Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
    3. finance.yahoo.com — MRNA Stock Soars Ahead Of Slated Return To Nasdaq-100; Retail ...
    4. www.gurufocus.com — Moderna (MRNA) Shares Surge on Cancer Vaccine Optimism ...
    5. www.biopharmadive.com — Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug | BioPharma Dive
    confidence 90%
  11. Moderna Cancer Vaccine Trial Success Triggers Massive Surge and Citi Downgrade

    Moderna shares have surged following positive Phase 3 results for intismeran autogene, an individualized neoantigen therapy combined with Merck's Keytruda in melanoma patients. The INTerpath-001 trial met its primary endpoints for recurrence-free survival and distant metastasis-free survival. While cancer experts praise the personalized mRNA approach, financial institutions warn that the soaring valuation has reached unsustainable levels. Citi downgraded the stock to sell with an $80 price target, citing extreme market expectations that leave little room for error despite the milestone clinical data.

    Why it matters

    The successful trial results validate personalized mRNA oncology after years of historical setbacks in the field. Merck exercised an option to collaborate on the personalized RNA-based cancer vaccine through a $250 million payment, cementing a partnership that began in 2016. Analysts highlight that manufacturing complexity, high costs, and reimbursement hurdles still pose commercial challenges for the platform.

    What is confirmed

    • Moderna and Merck announced positive topline results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene combined with Keytruda.
    • The Phase 3 trial met endpoints of recurrence-free survival and distant metastasis-free survival in the adjuvant melanoma setting.
    • Citi analyst Geoff Meacham downgraded Moderna to sell while raising the price target to $80.
    • Merck previously paid $250 million to take up an option on the personalized RNA-based cancer vaccine.

    Still unconfirmed

    • Laidlaw analyst Yale Jen flagged possible data releases in other cancers starting from 2027.
    • Moderna has engaged in talks with Middle East partners regarding potential investment and manufacturing cooperation.

    What to watch next

    • Upcoming presentations of detailed efficacy and manufacturing data at international medical meetings
    • Regulatory submissions by Merck and Moderna for intismeran autogene in combination with Keytruda
    Sources used for this update (20)
    1. madison.com — Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough
    2. 247wallst.com — Moderna Adds Another 5% and Is Up 500% in 2026. Can MRNA Stock Continue the Melt-Up?
    3. www.merck.com — Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoin....
    4. stocktwits.com — Nasdaq, S&P 500 Futures Fall As Oil Spikes On Trump’s Snub To Iran: MU, NVDA, SKHY, SPCX, NIO Stocks In....
    5. www.biopharmadive.com — Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data | BioPharma Dive
    6. bullishdaily.com — Moderna–Merck Melanoma Vaccine Success Reframes the ...
    7. finance.yahoo.com — Why Moderna (MRNA) Is Up 29.1% After Melanoma Vaccine Success ...
    8. pharmaphorum.com — Merck gets on board with Moderna cancer vaccine in $250m deal
    9. www.marketbeat.com — Morgan Stanley (MS) Stock Price, News & Analysis
    10. www.nature.com — RNA therapeutics: current status and future directions | Signal Transduction and Targeted Therapy
    11. stocktwits.com — MRNA Stock Eyes Best Year Ever: Analyst Calls China’s AI Drug Lead ‘Baseless’ As Moderna Awaits Can....
    12. pharmaphorum.com — MSD, Moderna start phase 3 trial of mRNA cancer jab
    confidence 100%
  12. Moderna Shares Rise After Phase 3 Melanoma Data Earns Symposium Slot

    Moderna shares rose 9% after the company secured a Presidential Symposium slot at Europe's leading oncology congress to present Phase 3 melanoma vaccine data. This price jump follows a monthly surge of 137% driven by the company's mRNA cancer pipeline. While the specific dataset remains unseen, the prestige of the presentation slot is driving market optimism. The company continues to manage high cash burn and competition from rivals like Amgen while operating in a cancer vaccine market projected to grow at a CAGR of 36% from 2026 to 2036.

    Why it matters

    Moderna is pivoting its mRNA technology from infectious diseases to oncology. The company previously saw stock gains between 7.1% and 9.37% following a presentation at the Morgan Stanley Global Healthcare Conference.

    What is confirmed

    • Moderna shares increased 9% following the announcement of a Presidential Symposium slot at Europe's top oncology congress.
    • The cancer vaccines market is projected to grow at a CAGR of 36% between 2026 and 2036.

    Still unconfirmed

    • The scheduling of the symposium slot signals positive results for the unseen Phase 3 melanoma dataset.

    What to watch next

    • Release of the actual Phase 3 melanoma dataset at the oncology congress.
    • Updated cash burn figures and financial reports from Moderna.
    Sources used for this update (2)
    1. 247wallst.com — Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher
    2. finance.yahoo.com — Cancer Vaccines Market Anticipates Impressive Growth Trajectory at a CAGR of 36% During the Forecast Period (2026-2036) | DelveInsight
    confidence 90%
  13. Moderna Shares Rise Following Cancer Vaccine Trial Results and Conference

    Moderna stock climbed between 7.1% and 9.37% on Thursday following the release of promising late-stage vaccine trial results and a presentation at the Morgan Stanley Global Healthcare Conference. These gains follow a monthly surge of 137% as investors react to the company's mRNA cancer vaccine pipeline. While the stock continues to climb, the company still faces high cash burn and competition from firms like Amgen.

    Why it matters

    The company's valuation has nearly tripled in one month. This growth reflects a shift in investor sentiment regarding the viability of mRNA technology for oncology.

    Still unconfirmed

    • Moderna stocks traded up 9.37 percent following promising late-stage vaccine trial results.
    • Shares jumped 7.1 percent after a presentation at the Morgan Stanley Global Healthcare Conference.

    What to watch next

    • Publication of the full late-stage trial data
    • Updated analyst valuations following the Morgan Stanley conference
    Sources used for this update (2)
    1. www.timothysykes.com — MRNA Stock Rockets As Cancer Breakthrough Redefines The Story
    2. finance.yahoo.com — Why Are Moderna (MRNA) Shares Soaring Today
    confidence 70%
  14. Moderna Shares Rise 6% as Monthly Gains Reach 137%

    Moderna stock increased 6% on Thursday, extending a monthly surge of 137% driven by the trade surrounding its mRNA cancer vaccine. The company's valuation has nearly tripled in one month. This growth occurs despite a lack of new trial results or analyst upgrades to justify the recent climb. BioNTech and Novavax shares also saw modest increases. Investors are weighing these gains against Moderna's continued cash burn and the valuation of competitors like Amgen.

    Why it matters

    Moderna is attempting to leverage its high share price to fund an expanded oncology pipeline. This strategy faces scrutiny from firms like Rothschild and Co., which downgraded the stock to sell. Analysts are comparing Moderna's spending patterns to revenue-generating peers in the biotech sector.

    What is confirmed

    • Moderna shares rose 6% on Thursday.
    • Moderna shares have increased 137% over the past month.
    • BioNTech and Novavax shares moved higher.

    Still unconfirmed

    • Moderna's stock has nearly tripled in a single month without new trial results or analyst upgrades.

    What to watch next

    • Release of new clinical trial results for the mRNA cancer vaccine
    • Further valuation adjustments from Rothschild and Co.
    • Revenue reports comparing Moderna's cash burn to Amgen's earnings
    Sources used for this update (3)
    1. jen.jiji.com — Sustainability: Institutions and businesses in Naples discuss sustainable transition (2)
    2. jen.jiji.com — New malaria alert in Germany, one dead and one infected: both live near Frankfurt airport
    3. finance.yahoo.com — Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher
    confidence 90%
  15. Moderna Valuation Faces Scrutiny Amid Oncology Success

    Moderna shares have doubled following the clinical success of its mRNA cancer vaccine, though the company continues to burn cash. This price surge led Rothschild and Co. to downgrade the stock from neutral to sell, citing an overvalued position. While Moderna seeks to use its high share price to fund a broader oncology pipeline, analysts are monitoring the competition between Moderna and BioNTech. Market comparisons now contrast Moderna's valuation with Amgen, which generates billions in revenue compared to Moderna's current spending patterns.

    Why it matters

    The oncology vaccine sector is a primary growth area for mRNA technology. Moderna's ability to secure funding for its pipeline depends on maintaining investor confidence despite high spending.

    What is confirmed

    • Rothschild and Co. downgraded Moderna stock from neutral to sell.
    • Moderna shares doubled due to the success of its mRNA cancer vaccine.

    Still unconfirmed

    • Amgen trades at a fraction of Moderna's valuation.
    • Moderna is burning cash while Amgen generates billions.

    What to watch next

    • Financial reports detailing Moderna's cash burn rate
    • Clinical trial updates for the oncology pipeline
    • Market share shifts between Moderna and BioNTech
    Sources used for this update (14)
    1. jen.jiji.com — 'When I see you again' is Gino Paoli's last unreleased song, the missed duet with Ornella Vanoni
    2. jen.jiji.com — Short-term rentals: open clash between EU, homeowners and tourist platforms
    3. jen.jiji.com — Juve, Locatelli underwent knee surgery: here's when he'll return to the field
    4. jen.jiji.com — Fabregas snubs Champions League debut: "It's just another game"
    5. jen.jiji.com — 'Red Bull 64 Bars Live', Ele A, Nerissima Serpe and Papa V as special guests: the live in Taranto
    6. jen.jiji.com — Vuelta a España, today 18th stage: time, route and where to watch it
    7. jen.jiji.com — Kefir superfood or current trend? Bassetti: "Here's what science really says"
    8. www.fool.com — Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
    9. jen.jiji.com — Agrigento, illegal house inherited from father: Deputy Mayor Crosta resigns
    10. jen.jiji.com — Weather, goodbye mugginess with the Azores High: but from Tuesday everything changes, rain arriving
    11. jen.jiji.com — Ostia, construction worker dies falling from crane basket. The other clings to the balcony: "Saved by the residents"
    12. jen.jiji.com — Food, Anir Confindustria: "For large-scale catering, more certainty on contracts and rules"
    confidence 80%
  16. Moderna Shares Double Following Success of mRNA Cancer Vaccine

    Rothschild and Co. has downgraded Moderna stock from neutral to sell because the firm considers the company overvalued. This valuation shift follows a price surge driven by the clinical success of Moderna's mRNA cancer vaccine. Wall Street analysts remain closely focused on the market competition between Moderna and BioNTech within the oncology vaccine sector. Moderna has attempted to leverage its elevated share prices to secure financial support for its broader oncology pipeline development, prompting the recent downgrade from the research firm.

    Why it matters

    Personalized mRNA cancer vaccines represent a developing frontier in oncology, drawing intense market interest and driving major stock fluctuations. Financial institutions are closely monitoring how biotech firms fund their clinical pipelines amid shifting valuations. Competition between major players like Moderna and BioNTech continues to dictate market sentiment.

    What is confirmed

    • Rothschild and Co. downgraded Moderna stock to sell from neutral, stating the company is now overvalued.
    • The valuation shift follows a surge in share prices driven by the success of Moderna's mRNA cancer vaccine.

    What to watch next

    • Further clinical trial results for mRNA cancer vaccines
    • Developments in the market competition between Moderna and BioNTech
    • Moderna's ongoing efforts to fund its oncology pipeline
    Sources used for this update (5)
    1. jen.jiji.com — Food: Barilla, with La tavolata reunites paddock family on the starting grid of Monza (2)
    2. jen.jiji.com — No more toilet paper, the 'smart toilet' arrives: what it is and how it works
    3. www.stl.news — Five Best-Performing Stocks of 2026 So Far
    4. www.usatoday.com — Personalized mRNA cancer vaccines offer new hope. We explain
    5. jen.jiji.com — AfD soars in Saxony-Anhalt, Vannacci: "Merz has an ulcer, let no one sleep"
    confidence 100%
  17. Rothschild & Co. Downgrades Moderna to Sell Following Stock Surge

    Rothschild & Co. has downgraded Moderna stock to sell from neutral, stating the company is now overvalued. This shift follows a surge in share prices driven by the success of Moderna's mRNA cancer vaccine. While Wall Street remains focused on the competition between Moderna and BioNTech in the cancer vaccine market, the research firm believes the current valuation exceeds the company's worth. This follows Moderna's recent efforts to capitalize on high share prices to fund its oncology pipeline.

    Why it matters

    Moderna developed a personalized neoantigen vaccine, intismeran autogene, with Merck that reduced melanoma recurrence risk by roughly half in a Phase 3 trial of 1,137 patients. To fund these initiatives, the company raised 2.6 billion dollars through an upsized convertible note offering.

    What is confirmed

    • Rothschild & Co. downgraded Moderna stock to sell from neutral.
    • Rothschild & Co. stated Moderna is now overvalued after a stock surge led by its cancer vaccine.

    What to watch next

    • Further analyst rating changes from other major research firms
    • Clinical updates or regulatory filings for intismeran autogene
    • Financial reports detailing the deployment of the 2.6 billion dollar capital raise
    Sources used for this update (8)
    1. jen.jiji.com — Tamberi and Bontempi, the fairytale party for their daughter Camilla's first birthday
    2. jen.jiji.com — Serie A, today Atalanta-Bologna: time, probable lineups and where to watch it on TV
    3. jen.jiji.com — USA, Bank of America Vice President is the woman stabbed to death in Times Square
    4. jen.jiji.com — US Open, Musetti and Bellucci in the second round
    5. finance.yahoo.com — Is BioNTech Stock a No-Brainer Buy on the Dip?
    6. jen.jiji.com — Vuelta a España, today twelfth stage: schedule, route and where to watch it
    7. www.cnbc.com — Moderna is now overvalued after cancer vaccine-led stock surge, Rothschild & Co. says
    8. www.fool.com — BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?
    confidence 100%
  18. Moderna Upsizes Funding to $2.6 Billion Following Cancer Vaccine Success

    Moderna has raised $2.6 billion through an upsized convertible note offering to fund its cancer vaccine initiatives. This financial move follows a Phase 3 trial of 1,137 patients where the personalized neoantigen vaccine intismeran autogene, developed with Merck, reduced melanoma recurrence risk by roughly half. The company is leveraging a multi-year high in share prices to secure this capital. Separately, the FDA has cleared updated COVID vaccines.

    Why it matters

    The funding supports the scale-up of mRNA technology for oncology. The intismeran autogene trial represents a significant shift from infectious disease to personalized cancer treatment.

    What is confirmed

    • Moderna raised $2.6 billion to support its cancer research.
    • The FDA cleared updated COVID vaccines.
    • Intismeran autogene reduced melanoma recurrence risk by roughly half in a Phase 3 trial of 1,137 patients.

    What to watch next

    • Updates on the commercial rollout of intismeran autogene
    • Further FDA approvals for mRNA cancer therapies
    Sources used for this update (6)
    1. jen.jiji.com — Girl dies of diphtheria in Palermo: autopsy underway
    2. www.newscase.com — BioNTech’s Sympathy Surge Masks a Structural Squeeze
    3. jen.jiji.com — Coffee at the bar, Stoppani (Fipe): "2 euro cup a remote hypothesis, but pay attention to energy and inflation"
    4. finance.yahoo.com — Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines
    5. jen.jiji.com — 16-year-old who had left home found lifeless in the Po river
    6. jen.jiji.com — Udine, woman stabbed to death: husband arrested
    confidence 100%
  19. Moderna Raises $2 Billion Following Cancer Vaccine Success

    Moderna is raising $2 billion through convertible notes due 2032 to capitalize on its recent stock surge. The company has an option to secure an additional $300 million. This financial move follows the announcement that Moderna and Merck's personalized neoantigen vaccine, intismeran autogene, reduced melanoma recurrence risk by roughly half in a Phase 3 trial of 1,137 patients. While shares hit a multi-year high, the company is now leveraging that valuation to secure funding for its cancer vaccine initiatives.

    Why it matters

    The funding follows a period of high volatility where shares peaked and then dipped 5.13% on August 24 due to profit-taking. Moderna's partnership with Merck represents a significant shift toward mRNA cancer therapies. This development occurs as competitors like BioNTech face financial losses and restructuring.

    What is confirmed

    • Moderna is selling convertible notes due 2032 to raise $2 billion.
    • Moderna has an option to raise an additional $300 million.
    • A Phase 3 trial of 1,137 patients showed the intismeran autogene vaccine reduced melanoma recurrence risk by roughly half.
    • Moderna shares fell 5.13% on August 24.

    What to watch next

    • Analysts' updates to price targets following the $2 billion capital raise
    • Regulatory approval timelines for intismeran autogene
    Sources used for this update (9)
    1. en.protothema.gr — What K.M. & Tsipras say about the elections, the phantom investor and the crème de la crème, bonuses at Astieras & shipowners selling tankers
    2. jen.jiji.com — European Volleyball Championship, Italy-France 3-1: Azzurre to the round of 16 as group winners
    3. finance.yahoo.com — Moderna raises $2 billion in convertible notes for cancer vaccine
    4. jen.jiji.com — Atalanta beats Hapoel 1-0 and qualifies for the Conference League
    5. jen.jiji.com — Heat, how to face tropical nights: the four (fundamental) tips from the expert
    6. jen.jiji.com — Ranucci, Esperia: "In the book he says Gabanelli called him while he was saving a man, but a video with another version emerges"
    7. jen.jiji.com — Ukraine, Russian raids on 'Nova Post' warehouses in Kyiv region
    8. uk.finance.yahoo.com — Merck (MRK) Stock Looks Fully Priced After A 127% Run
    9. www.ad-hoc-news.de — BioNTech's Balancing Act: A New CEO, a Costly Pivot, and a Pipeline That Must Prove Itself
    confidence 100%
  20. Moderna mRNA Cancer Vaccine Halves Melanoma Recurrence in Phase 3 Trial

    Moderna and Merck announced on August 19 that their personalized neoantigen vaccine, intismeran autogene, reduced the risk of melanoma recurrence by roughly half. The Phase 3 trial included 1,137 patients. While the stock surged following the results, Moderna shares fell 5.13% on August 24 as investors engaged in profit-taking and valuation resets. Analysts continue to maintain cautious price targets that remain well below the stock's temporary peak.

    Why it matters

    This trial represents the first personalized neoantigen vaccine to clear Phase 3. The partnership between Moderna and Merck aims to prevent skin cancer from returning after initial treatment.

    What is confirmed

    • Moderna and Merck announced positive Phase 3 results for their personalized mRNA cancer vaccine.
    • The vaccine, intismeran autogene, cut melanoma recurrence risk by roughly half in 1,137 patients.
    • Moderna shares moved down by 5.13% on August 24.

    What to watch next

    • Regulatory filing dates for intismeran autogene
    • Updated analyst price targets following the valuation reset
    Sources used for this update (4)
    1. en.protothema.gr — Mitsotakis’s order to “round up the ripe ones living off public money,” the Thessaloniki Fair, Tsipras and Samaras, the Spetses tip-offs, and is George Papandreou’s son ...
    2. consent.yahoo.com — Moderna and Merck Cancer Vaccine Success Is Good News for CancerVax
    3. www.tradingkey.com — Moderna Inc Stock (MRNA) Moved Down by 5.13% on Aug 24: A Full Analysis
    4. www.techtimes.com — Personalized mRNA Cancer Vaccine Clears Phase 3: Melanoma Recurrence Cut by Half
    confidence 90%
  21. Moderna Shares Double on mRNA Cancer Vaccine Success

    Moderna's shares have more than doubled following promising results from its mRNA cancer vaccine, developed in collaboration with Merck, in a late-stage melanoma trial. The vaccine shows potential in preventing skin cancer recurrence. The trial involved over 1,000 patients and demonstrated a significant reduction in cancer recurrence.

    Why it matters

    The success of Moderna's mRNA cancer vaccine could pave the way for a new wave of cancer treatments. The vaccine uses a personalized neoantigen therapy approach, which involves tailoring the treatment to individual patients. This breakthrough has significant implications for the future of cancer treatment and could lead to the development of similar vaccines for other types of cancer.

    What is confirmed

    • Moderna's mRNA cancer vaccine helped prevent the return and spread of melanoma in a trial involving more than 1,000 patients.
    • Moderna's shares have more than doubled on the success of its mRNA cancer vaccine.
    • BioNTech shares jumped 24% on Moderna's cancer vaccine success, highlighting mRNA platform potential.
    • The vaccine's success could usher in a wave of cancer vaccines.

    Still unconfirmed

    • It is unclear if the vaccine's success will be a one-off or open a portal to a new way of treating cancers in general.

    What to watch next

    • Further trial results and FDA approval
    • Development of similar vaccines for other types of cancer
    • Impact on Moderna's and Merck's stock prices
    Sources used for this update (5)
    1. www.livemint.com — It now seems possible to vaccinate against cancer
    2. omaha.com — Moderna, Merck breakthrough could usher in cancer vaccines
    3. www.ad-hoc-news.de — BioNTech's Sympathy Surge: When a Rival's Data Becomes Your Stock's Best Friend
    4. www.genengnews.com — StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too
    5. www.theglobeandmail.com — Why Tempus AI Skyrocketed This Week
    confidence 85%
  22. Moderna Shares Double on mRNA Cancer Vaccine Success

    Moderna's shares have doubled amid promising results from its mRNA cancer vaccine, developed in collaboration with Merck, in a late-stage melanoma trial. The vaccine shows potential in preventing skin cancer recurrence. Moderna's shares have seen significant fluctuations, rising 8% on Friday.

    Why it matters

    The success of Moderna's mRNA cancer vaccine marks a significant moment in cancer treatment, offering new hope for patients. The vaccine is a personalized treatment that may help prevent skin cancer from recurring. This development has substantial implications for the future of cancer therapy.

    What is confirmed

    • Moderna's shares have doubled on the success of its mRNA cancer vaccine
    • The mRNA cancer vaccine shows promise in preventing skin cancer recurrence
    • Moderna's shares have seen significant fluctuations, rising 8% on Friday

    What to watch next

    • Further trial results for the mRNA cancer vaccine
    • Regulatory decisions on the vaccine's approval
    • Long-term efficacy and safety data for the vaccine
    Sources used for this update (6)
    1. baynews9.com — New study shows personalized vaccine may help prevent skin cancer from recurring in patients
    2. 247wallst.com — Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session
    3. www.aol.com — Moderna's Comeback Is Finally Taking Shape -- and There May Be More Upside Ahead
    4. en.sedaily.com — SK hynix to Buy Back, Cancel 40 Trillion Won in Shares; KOSPI Retakes 6,800
    5. en.sedaily.com — Korea to Build 2 More Chip Fabs in Honam, Adding to 6-Plus Plan by 2040
    6. www.cheddar.com — Big Business This Week: Bond Market Turmoil and The Broader Economy
    confidence 85%
  23. Moderna Shares Double on mRNA Cancer Vaccine Success

    Moderna and Merck's mRNA cancer vaccine showed promise in a late-stage melanoma trial, with Moderna's shares soaring 90%. The vaccine, a collaboration between the two companies, has doubled Moderna's shares. This development could mark a significant moment in cancer treatment.

    Why it matters

    The mRNA cancer vaccine is a collaboration between Moderna and Merck, two major pharmaceutical companies. The vaccine's success in a late-stage trial could pave the way for a new approach to cancer treatment. Moderna's stock has seen significant gains following the announcement. The companies' work on mRNA technology has been closely watched by the medical community.

    What is confirmed

    • Moderna and Merck's mRNA cancer vaccine succeeded in a late-stage melanoma trial.
    • Moderna's shares soared 90% following the announcement.

    What to watch next

    • Further details on the trial results
    • Regulatory approval process for the vaccine
    • Potential impact on cancer treatment options
    Sources used for this update (5)
    1. STAT — Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
    2. CNBC — Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90%
    3. The Washington Post — Cancer treatment could face landmark moment with promising vaccine
    4. WSJ — Moderna Shares Double on Success of mRNA Cancer Vaccine
    5. Bloomberg.com — Watch Moderna Surges on Cancer Vaccine; Estee Lauder Rallies on Earnings | Stock Movers
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community